Live feed08:00:00·612dPRReleasevia QuantisnowVertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual MeetingByQuantisnow·Wall Street's wire, on your screen.VRTX· Vertex Pharmaceuticals IncorporatedHealth Care
